Clinical Trial

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

Name: IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome — clinical trial record (NCT03744390)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

patients with MDS (Myelodysplastic Syndrome) and mutated IDH2 patients will be treated with AG221 (IDH2 inhibitor)

Protocol Amendment History 1 change

minor Completion pushed: 2026-03-18 -> 2026-12-18 2026-08-11

Trial Details

NCT Number	NCT03744390
Lead Sponsor	Groupe Francophone des Myelodysplasies
Conditions	Myelodysplastic Syndromes, Leukemia Acute Myeloid
Enrollment	68 participants
Start Date	2019-04-02
Primary Completion	2023-02-18 (estimated)
Study Completion	2026-12-18 (estimated)
Updated on ClinicalTrials.gov	2026-08-10